• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

    5/27/25 8:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email

    AUSTIN, Texas, May 27, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

    The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ:NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.

    During the interview, Sheridan provided an introduction to Nutriband's business model.

    "We're a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We're all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We're tackling this head-on with our AVERSA™ technology."

    "It is a platform tech that we've developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we're also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people's vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we've seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products."

    "You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They're under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We're looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That's something that we'll tackle head-on with our AVERSA technology."

    Join IBN's Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company's development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.

    To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

    The latest installment of The BioMedWire Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

    To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

    About Nutriband Inc.

    Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

    For more information, visit the company's website at www.Nutriband.com

    About IBN

    IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

    Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

    For more information, please visit https://www.InvestorBrandNetwork.com

    Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

    Corporate Communications

    IBN

    Austin, Texas

    www.InvestorBrandNetwork.com

    512.354.7000 Office

    [email protected]



    Primary Logo

    Get the next $NTRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nutriband Inc.

      10-Q - NutriBand Inc. (0001676047) (Filer)

      5/30/25 4:02:06 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Amendment: SEC Form 10-K/A filed by Nutriband Inc.

      10-K/A - NutriBand Inc. (0001676047) (Filer)

      5/13/25 5:29:18 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Nutriband Inc.

      10-K - NutriBand Inc. (0001676047) (Filer)

      4/28/25 5:21:20 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Nutriband with a new price target

      Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

      1/22/25 9:24:55 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Leadership Updates

    Live Leadership Updates

    See more

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NTRB
    Financials

    Live finance-specific insights

    See more
    • Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

      The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

      5/16/24 7:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

      ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.  Scheduled 1x1 meetings with the Company are also available for registered, qualified investor attendees. Attendees interested in viewing the live presentation can register for this event, at no cost, here: Virtual Equity Conference Registration A video webcast of the presentation will be available fol

      6/3/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

      ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS and the increasing Pocono revenue stream is key to the company's focus on shareholder v

      6/2/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

      AUSTIN, Texas, May 27, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ:NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products. Duri

      5/27/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Nutriband Inc. Commences Trading on Upstream Under NTRB

      Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto

      1/5/23 6:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Will Be the First Company to Dual List on Upstream

      Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u

      12/30/22 6:30:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

      SC 13D/A - NutriBand Inc. (0001676047) (Subject)

      9/19/24 11:38:15 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/13/24 8:33:52 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/12/24 3:57:44 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Goodman Gerald

      4 - NutriBand Inc. (0001676047) (Issuer)

      12/2/24 3:49:25 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by President and Secretary Melnik Serguei

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:58:08 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by CEO Sheridan Gareth

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:11:33 PM ET
      $NTRB
      Industrial Specialties
      Health Care